| |
| Device | HER2 Dual ISH DNA Probe Cocktail |
| Generic Name | Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer |
| Regulation Number | 864.1890 |
| Applicant | Ventana Medical Systems, Inc. 1910 E. Innovation Park Dr. Tucson, AZ 85755 |
| PMA Number | P190031 |
| Supplement Number | S015 |
| Date Received | 08/15/2025 |
| Decision Date | 05/15/2026 |
| Reclassified Date | 09/16/2026 |
| Product Code |
NYQ |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT05113251
|
| Supplement Type | Normal 180 Day Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval to include HER2 Dual ISH DNA Probe Cocktail as a companion diagnostic indication for the determination of HER2 gene amplification status in patients with breast cancer who may benefit from treatment with ENHERTU® (fam-trastuzumab deruxtecan-nxki). |